title: The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies.
abstract: Psoriatic Arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis. Psoriasis (PsO) is a chronic, inflammatory skin disease, characterized by hyperproliferation and aberrant differentiation of keratinocytes. PsA and PsO can be considered as a unique disease and are immune-mediated diseases and both innate and adaptive immunity play a role in their pathogenesis. Initially, PsO and PsA were thought to be Th1-mediated diseases, however, in the last years, several studies have shown the role of interleukin 17 (IL-17) and Th17 cells in the pathogenesis of PsA and PsO. Th17 cells have been detected in dermal infiltrates of psoriatic lesions as well as in synovial fluid. Interleukin (IL)-23, produced by antigen presenting cells (APC), especially by dendritic cells (DC), is the key regulator cytokine for Th17 and IL-17 production. In this review we discuss the role of IL-17 and IL-23 in the pathogenesis of PsO and PsA and their role as therapeutic targets for PsO and PsA treatment.
authors.affiliation: Rheumatology, Allergology and Clinical Immunology, Department of Internal Medicine, University of Tor Vergata, Rome, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Novelli
authors.forename: Maria Sole
authors.initials: MS
authors.lastname: Chimenti
authors.forename: Andrea
authors.initials: A
authors.lastname: Chiricozzi
authors.forename: Roberto
authors.initials: R
authors.lastname: Perricone
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000906:Antibodies; D020381:Interleukin-17; D053759:Interleukin-23
keywords: IL-17; IL-23; Psoriasis; Psoriatic arthritis; Th17 cells; Therapeutic targets